China SXT Pharmaceuticals, Inc.

SXTC

VGG2161P1403

Pharmaceuticals

Delayed Nasdaq Other stock markets 12:59:46 2024-07-03 EDT			5-day change	1st Jan Change
1.05 ^USD	-2.78%		-1.87%	-73.55%

05-13	China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	CI
05-09	China SXT Pharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding from Streeterville Capital, LLC	CI

China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC

May 12, 2024

On May 13, 2024, China SXT Pharmaceuticals, Inc. closed the transaction.

Latest news about China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	05-12	CI
China SXT Pharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding from Streeterville Capital, LLC	05-08	CI
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	04-05	CI
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	02-08	MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	02-08	MT
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	01-02	MT
US Equity Futures Set Kick Off 2024 Lower Ahead of Manufacturing PMI, Construction Data	01-02	MT
China SXT Pharmaceuticals to Implement 1-for-25 Reverse Stock Split	23-10-04	MT
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-31	CI
China SXT Pharmaceuticals, Inc. announced that it has received $2 million in funding from Streeterville Capital, LLC	23-03-06	CI
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2022	23-02-24	CI
China SXT Pharmaceuticals, Inc. announced that it has received $1.5 million in funding from Streeterville Capital, LLC	22-12-19	CI
China SXT Pharmaceuticals, Inc. announced that it expects to receive $1.5 million in funding from Streeterville Capital, LLC	22-12-18	CI
Top Premarket Gainers	22-12-05	MT
China SXT Pharmaceuticals, Inc. announced that it has received $2.194827 million in funding	22-09-21	CI
China SXT Pharmaceuticals, Inc. announced that it expects to receive $2.194827 million in funding	22-09-21	CI
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-07-18	CI
China SXT Pharmaceuticals Effects 1-for-20 Reverse Stock Split; Shares Decline	22-05-18	MT
China SXT Pharmaceuticals, Inc. Announces Resignation of Jingzhen Deng as Chief Scientific Officer and Chief Operation Officer	22-05-11	CI
Top Premarket Gainers	22-03-29	MT
China SXT Pharmaceuticals Agrees to Issue $2.8 Million of Convertible Promissory Notes to Streeterville Capital	22-03-15	MT
China SXT Pharmaceuticals, Inc. Announces Executive Changes	22-01-31	CI
Health Care Fall Tuesday But Resist Steepest Declines	22-01-18	MT
Sector Update: Health Care	22-01-18	MT
Top Midday Decliners	22-01-18	MT

Chart China SXT Pharmaceuticals, Inc.

Duration

Period

More charts

China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The Company sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA SXT PHARMACEUTICALS, INC.	-73.55%	764K
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.16%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.71%	238B
ROCHE HOLDING AG	-0.74%	221B
NOVARTIS AG	+14.49%	218B
AMGEN INC.	+7.42%	166B